ClinicalTrials.gg
CompletedNCT01221272Updated Sep 3, 2014Results posted

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

A Phase 4 interventional study of Ranolazine and Placebo to match ranolazine in Myocardial Perfusion Imaging and Myocardial Ischemia, sponsored by Gilead Sciences. Completed at 43 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-03.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 218 studies in Myocardial Ischemia with a site in United States — 23 open to participants now, 26 under way, none of them phase 3. Myocardial Ischemia · United States.

Enrollment
76th of 150
81 · median 87
Started
2010
with 13 others
Phase 4
19 of 218
none open now
Registered
97th of 218
by date

Among the 218 studies in Myocardial Ischemia with a site in United States, this one is the 76th largest by enrollment of the 150 interventional ones that give a count, is one of 14 that started in 2010, is one of 19 in phase 4, and was the 97th registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

23 of the 218 studies in Myocardial Ischemia with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies in Myocardial Ischemia with a site in United States, or all of them as a file.
02

Study summary

This study enrolled participants with documented exercise-induced myocardial ischemia in order to evaluate whether ranolazine, when taken prior to exercise, can improve blood flow to the heart (myocardial perfusion), as assessed by exercise-induced myocardial perfusion defect size (PDS) and total perfusion deficit (TPD), using gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI).

This was a 2-period crossover study. The last dose of each period must have been taken 3-4 hours prior to conduct of the exercise SPECT MPI. After the research exercise SPECT MPI was performed at the end of Period 1, participants discontinued the treatment they were randomized to for that period and began the other treatment in Period 2.

03

Conditions studied

  • Myocardial Perfusion Imaging
  • Myocardial Ischemia

Browse trials for

Keywords

  • SPECT MPI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Exercise SPECT MPI study (stress and rest) showing at least 10% reversible myocardial ischemia (as confirmed by the core nuclear laboratory using Corridor4DM imaging software) performed not more than 12 weeks prior to screening, OR
  • Exercise SPECT MPI study (stress and rest) conducted during screening (after consultation with the Medical Monitor and after was obtained) showing at least 10% reversible myocardial ischemia (as confirmed by the core nuclear laboratory)
  • Stable antianginal medical therapy (excluding short-acting nitroglycerin)

Key Exclusion Criteria:

  • Left bundle branch block
  • Automated implantable defibrillator and/or pacemaker (selected subjects with permanent pacemakers who had an intact sinus mechanism may have been included following consultation with the Medical Monitor)
  • Intervening coronary revascularization between the time of qualifying exercise SPECT MPI study and randomization
  • Acute myocardial infarction (MI) within 60 days prior to screening or at any time after the qualifying exercise SPECT MPI study, or MI undergoing staged intervention during a subject's participation in the trial
  • Unstable angina within 30 days prior to screening, or at any time after the qualifying exercise SPECT MPI study
  • Coronary artery bypass graft surgery within 60 days prior to screening or at any time after the qualifying exercise SPECT MPI study, or percutaneous coronary intervention within 30 days prior to screening or at any time after the qualifying exercise SPECT MPI study
  • Anticipated coronary revascularization during the trial period
  • Cerebrovascular attack or within 90 days prior to screening
  • History of serious arrhythmias
  • Current atrial fibrillation or atrial flutter
  • > 500 milliseconds
  • Diagnosed as having Class III or IV heart failure
  • Inability to exercise or exercise limitation due to other comorbidities that may have interfered with ability to perform required exercise SPECT MPI study
  • greater than or equal to 38 kg/m\^2 (may have been up to 40 kg/m\^2 after consultation with the Medical Monitor)
  • Any absolute to exercise stress testing
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Ranolazine/Placebo

    Participants received ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.

    Drug: Ranolazine · Drug: Placebo to match ranolazine · Procedure: SPECT MPI · Behavioral: Exercise

  • Experimental
    Placebo/Ranolazine

    Participants received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.

    Drug: Ranolazine · Drug: Placebo to match ranolazine · Procedure: SPECT MPI · Behavioral: Exercise

Interventions

  • * One 500 mg tablet in the evening on Day 1 of the period * One 500 mg tablet, twice daily on Days 2-3 of the period * Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)

    Also known as: Ranexa®

  • DrugPlacebo to match ranolazine

    Placebo to match ranolazine administered in the same form and frequency as the active drug.

  • ProcedureSPECT MPI

    Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.

  • BehavioralExercise

    Treadmill stress test

06

What researchers measure

Primary outcomes

  1. Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment

    PDS is the amount (percent) of the myocardium with decreased blood flow. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by gated single photon emission computed tomography (SPECT) imaging following exercise at the end of the ranolazine and placebo treatment periods.

    Time frame: Up to 33 days

  2. Exercise-induced Total Perfusion Deficit (TPD) Following Ranolazine and Placebo Treatment

    TPD is a score that measures the overall impact of a region of decreased myocardial blood flow, incorporating both the amount and severity of the decreased flow. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging following exercise at the end of the ranolazine and placebo treatment periods.

    Time frame: Up to 33 days

Secondary outcomes

  1. Perfusion Defect Severity at Baseline, End of Period 1, and End of Period 2

    Perfusion defect severity was assessed for each participant as the percentage of the 17 myocardium segments with a relative perfusion defect score of 3 or 4 on a 0-4 scale. Segment scores are: 0 = normal perfusion; 1 = mild reduction in counts-not definitely abnormal; 2 = moderate reduction in counts-definitely abnormal; 3 = severe reduction in counts; 4 = absent uptake (lower scores correspond to less severity and higher scores correspond to increased severity). A lower percentage means fewer segments have severely reduced blood flow. Measurements were obtained by SPECT imaging following exercise at baseline and at the end of Periods 1 and 2.

    Time frame: Up to 33 days

  2. Exercise-induced Reversible Perfusion Defect Size (PDS) at Baseline, End of Period 1, and End of Period 2

    Exercise-induced reversible PDS was derived as the exercise PDS at baseline and at the end of Periods 1 and 2 minus the resting PDS at baseline. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2.

    Time frame: Up to 33 days

  3. Exercise-induced Reversible Total Perfusion Deficit (TPD) at Baseline, End of Period 1, and End of Period 2

    Exercise-induced reversible TPD was derived as the exercise TPD at baseline and at the end of Periods 1 and 2 minus the resting TPD at baseline. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2.

    Time frame: Up to 33 days

07

Results

Posted Sep 3, 2014

Participant flow

Participants were enrolled in a total of 27 study sites in the United States, Canada, Czech Republic, and Israel. The first participant was screened on 29 September 2010. The last participant observation was on 27 September 2012.

Period 1
Participant flow — Period 1
MilestoneRanolazine/PlaceboPlacebo/Ranolazine
Started4140
Completed3938
Not completed22
Withdrew: Adverse event20
Withdrew: Consent withdrawal01
Withdrew: Significant dosing noncompliance01
Period 2
Participant flow — Period 2
MilestoneRanolazine/PlaceboPlacebo/Ranolazine
Started3939
Completed3937
Not completed02
Withdrew: Adverse event02

Outcome measures

PrimaryExercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment

PDS is the amount (percent) of the myocardium with decreased blood flow. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by gated single photon emission computed tomography (SPECT) imaging following exercise at the end of the ranolazine and placebo treatment periods.

Time frame:
Up to 33 days
Reported as:
Least squares mean · percentage of myocardium
Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment
percentage of myocardiumRanolazinePlacebo
Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment21.54 ± 1.5120.87 ± 1.51
Statistical analysis
  • Ranolazine vs Placebo · Mixed Models Analysis · p = 0.29 (The null hypothesis that ranolazine treatment had no effect on PDS would be rejected if the PDS and TPD p-values were less than 0.05 or the PDS p-value was less than 0.05/2 = 0.025.) · Mixed models analysis: 0.67 · 95% CI -0.6 to 1.9
PrimaryExercise-induced Total Perfusion Deficit (TPD) Following Ranolazine and Placebo Treatment

TPD is a score that measures the overall impact of a region of decreased myocardial blood flow, incorporating both the amount and severity of the decreased flow. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging following exercise at the end of the ranolazine and placebo treatment periods.

Time frame:
Up to 33 days
Reported as:
Least squares mean · units on a scale
Exercise-induced Total Perfusion Deficit (TPD) Following Ranolazine and Placebo Treatment
units on a scaleRanolazinePlacebo
Exercise-induced Total Perfusion Deficit (TPD) Following Ranolazine and Placebo Treatment17.23 ± 1.2616.57 ± 1.26
Statistical analysis
  • Ranolazine vs Placebo · Mixed Models Analysis · p = 0.22 (The null hypothesis that ranolazine treatment had no effect on TPD would be rejected if the PDS and TPD p-values were less than 0.05 or the TPD p-value was less than 0.05/2 = 0.025.) · Mixed models analysis: 0.65 · 95% CI -0.4 to 1.7
SecondaryPerfusion Defect Severity at Baseline, End of Period 1, and End of Period 2

Perfusion defect severity was assessed for each participant as the percentage of the 17 myocardium segments with a relative perfusion defect score of 3 or 4 on a 0-4 scale. Segment scores are: 0 = normal perfusion; 1 = mild reduction in counts-not definitely abnormal; 2 = moderate reduction in counts-definitely abnormal; 3 = severe reduction in counts; 4 = absent uptake (lower scores correspond to less severity and higher scores correspond to increased severity). A lower percentage means fewer segments have severely reduced blood flow. Measurements were obtained by SPECT imaging following exercise at baseline and at the end of Periods 1 and 2.

Time frame:
Up to 33 days
Reported as:
Mean · percentage of segments
Perfusion Defect Severity at Baseline, End of Period 1, and End of Period 2
percentage of segmentsRanolazine/PlaceboPlacebo/Ranolazine
Baseline11.4 ± 2.08.5 ± 2.0
End of Period 111.6 ± 1.910.2 ± 2.1
End of Period 210.4 ± 1.99.5 ± 2.0
SecondaryExercise-induced Reversible Perfusion Defect Size (PDS) at Baseline, End of Period 1, and End of Period 2

Exercise-induced reversible PDS was derived as the exercise PDS at baseline and at the end of Periods 1 and 2 minus the resting PDS at baseline. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2.

Time frame:
Up to 33 days
Reported as:
Mean · percentage of myocardium
Exercise-induced Reversible Perfusion Defect Size (PDS) at Baseline, End of Period 1, and End of Period 2
percentage of myocardiumRanolazine/PlaceboPlacebo/Ranolazine
Baseline exercise minus baseline resting12.5 ± 1.113.5 ± 1.3
End of Period 1 exercise minus baseline resting12.7 ± 1.214.1 ± 1.4
End of Period 2 exercise minus baseline resting12.4 ± 1.015.2 ± 1.4
SecondaryExercise-induced Reversible Total Perfusion Deficit (TPD) at Baseline, End of Period 1, and End of Period 2

Exercise-induced reversible TPD was derived as the exercise TPD at baseline and at the end of Periods 1 and 2 minus the resting TPD at baseline. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2.

Time frame:
Up to 33 days
Reported as:
Mean · units on a scale
Exercise-induced Reversible Total Perfusion Deficit (TPD) at Baseline, End of Period 1, and End of Period 2
units on a scaleRanolazine/PlaceboPlacebo/Ranolazine
Baseline exercise minus baseline resting10.5 ± 0.910.5 ± 1.0
End of Period 1 exercise minus baseline resting10.5 ± 0.910.7 ± 1.0
End of Period 2 exercise minus baseline resting10.1 ± 0.811.6 ± 1.1

Adverse events

Collected over Up to 33 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Onset Following Ranolazine—2/80 (2.5%)25/80 (31.3%)
Onset Following Placebo—0/79 (0%)7/79 (8.9%)
Onset at Any Time Following Ranolazine—2/80 (2.5%)28/80 (35%)
Most frequent serious events
Most frequent serious events
EventOnset Following RanolazineOnset Following PlaceboOnset at Any Time Following Ranolazine
BronchitisInfections and infestations1/800/791/80
Electrocardiogram ST segment elevationInvestigations1/800/791/80
Most frequent other events
Most frequent other events
EventOnset Following RanolazineOnset Following PlaceboOnset at Any Time Following Ranolazine
DizzinessNervous system disorders11/800/7911/80
DyspnoeaRespiratory, thoracic and mediastinal disorders7/802/799/80
ConstipationGastrointestinal disorders6/801/796/80
NauseaGastrointestinal disorders5/802/795/80
Angina pectorisCardiac disorders3/801/794/80
HeadacheNervous system disorders3/803/794/80

Baseline characteristics

Safety Analysis Set

Age, Continuous
Age, Continuous(years)All Participants
Mean66 ± 9.0
Age, Customized
Age, Customized(participants)All Participants
18 to 39 years0
40 to 64 years29
65 to 74 years39
≥ 75 years13
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female6
Male75
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Participants
White72
African-American5
Other4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Participants
Hispanic Or Latino9
Not Hispanic Or Latino62
Not Reported5
Unknown5
Region of Enrollment
Region of Enrollment(participants)All Participants
United States38
Czech Republic2
Canada27
Israel14
Body mass index
Body mass index(kg/m^2)All Participants
Mean29.6 ± 3.8
Weight
Weight(kg)All Participants
Mean88.6 ± 14.2
08

Study locations

43 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Imperial Cardiac Center
    Imperial, California 92251, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Mission Internal Medical Group
    Mission Viejo, California 92691, United States
  • Central Coast Cardiology
    Salinas, California 93901, United States
  • Alfieri Cardiology
    Newark, Delaware 19713, United States
  • St. Luke's Cardiology Associates
    Jacksonville, Florida 32216, United States
  • Cardiovascular Research Center of South Florida
    Miami, Florida 33173, United States
  • Research One
    Orlando, Florida 32806, United States
  • Cardiology Partners Clinical Research Institute
    Wellington, Florida 33449, United States
  • Fox Valley Clinical Research Center, LLC
    Aurora, Illinois 60504, United States
  • Research Integrity, LLC
    Owensboro, Kentucky 42303, United States
  • Louisiana Heart Center
    Covington, Louisiana 70403, United States
  • Louisiana Heart Center
    Slidell, Louisiana 70458, United States
  • Androscroggin Cardiology Associates DBA Maine Research Associates
    Auburn, Maine 04210, United States
  • Delmarva Heart Research Foundation, Inc
    Salisbury, Maryland 21804, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Cardiovascular Imaging Technologies
    Kansas City, Missouri 64111, United States
  • Dr. Michael Sacher
    Massapequa, New York 11758, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Heritage Cardiology
    Camp Hill, Pennsylvania 17011, United States
  • University of Pittsburgh Medical Center Cardiovascular Institute
    Pittsburgh, Pennsylvania 15213, United States
  • Kore Cardiovascular Research
    Jackson, Tennessee 38305, United States
  • East Texas Cardiology PA
    Houston, Texas 77002, United States
  • Mercury Medical, LLC
    San Antonio, Texas 78229, United States
  • University of Ottawa Heart Institute
    Ottawa, Ontario K1Y 4W7, Canada
  • ECOGENE-21 Clinical Trial Center, Chicoutimi Hospital
    Chicoutimi, Quebec G7H 7P2, Canada
  • Montreal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
  • Chum Hotel Dieu
    Montreal, Quebec H2W 1T8, Canada
  • University Hospital Kralovske Vinohrady
    Praha 10, 100 34, Czech Republic
  • University Hospital Motol
    Praha 5, 150 06, Czech Republic
  • Turku University Hospital
    Turku, 20520, Finland
  • Barzilai Medical Center
    Ashkelon, 78278, Israel
  • Soroka Medical Center
    Beer Sheva, 84101, Israel
  • Rambam Health Care Campus
    Haifa, 31096, Israel
  • Kaplan Medical Center
    Rehovot, 76100, Israel
  • Assuta MC
    Tel Aviv, 69710, Israel
  • "Federico II" University
    Naples, 80131, Italy
  • Federico II University
    Naples, 80131, Italy
  • National University Health System
    Singapore, 119228, Singapore
  • National Heart Centre Singapore
    Singapore, 168752, Singapore
  • Northwick Park Hospital, Watford Road
    Middlesex, HA1 3UJ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 2 years after primary completion. A results delay was requested in Aug 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2010
First posted
Oct 14, 2010
Start
Sep 2010
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results delay requested
Aug 8, 2013
Results first posted
Sep 3, 2014
Last update
Sep 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01221272
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 14, 2010
Start date
Sep 2010
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Sep 3, 2014
Last update
Sep 3, 2014

Study contacts

Patrick Yue, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion